GOVX (Geovax Labs) Quality Rank

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Geovax Labs Quality Rank Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Geovax Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Executives

David A Dodd	director	C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds	officer: Chief Financial Officer	TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Mckee Kelly T. Jr.	officer: Chief Medical Officer	233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
Jayne Morgan	director	1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase	director	28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey	officer: VP, Business Development	16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas	director	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr	director	2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally	director
Farshad Guirakhoo	officer: Sr VP, Research & Development	39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi	director	10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson	other: Chair, Scientific Adv Brd	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman	officer: VP, Research & Development	1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas	director	123 JOAN DRIVE, BARRINGTON IL 60010